文献速递妇科

尼拉帕利疗效与手术时机及术后残留病灶状态的关系:PRIMA/ENGOT-OV26/GOG-3012 研究的事后分析

Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
PubMed 文献 · Gynecol Oncol · 2022-05-09

该事后分析基于 III 期 PRIMA/ENGOT-OV26/GOG-3012 研究(N=733),评估新诊断晚期卵巢癌患者中手术时机(初次减瘤术 vs 新辅助化疗/间歇性减瘤术)及术后残留病灶状态对尼拉帕利一线维持治疗疗效的影响,结果显示各手术亚组中尼拉帕利疗效相似,新辅助化疗/间歇性减瘤术且肉眼可见残留病灶者进展风险降低最明显。

要点

  • PRIMA 研究中 236 例(32.2%)接受初次减瘤术,481 例(65.6%)接受新辅助化疗/间歇性减瘤术。
  • 初次减瘤术亚组中尼拉帕利 vs 安慰剂中位无进展生存期 13.7 vs 8.2 个月(HR 0.67,95%CI 0.47-0.96)。
  • 新辅助化疗/间歇性减瘤术且肉眼可见残留病灶者 HR 0.41(95%CI 0.27-0.62),进展风险降低最明显。

核心结论

  • 在该事后分析中,尼拉帕利在初次减瘤术和新辅助化疗/间歇性减瘤术亚组间的疗效相似。
  • 接受新辅助化疗/间歇性减瘤术且肉眼可见残留病灶的患者,尼拉帕利维持治疗带来的进展风险降低最明显。

研究设计与样本

  • PRIMA/ENGOT-OV26/GOG-3012(NCT02655016)III 期研究的事后分析。
  • 研究对象为新诊断原发性晚期卵巢癌、原发性腹膜癌或输卵管癌且对一线铂类化疗达到完全或部分缓解的患者。
  • 在意向治疗人群中,按手术状态(初次减瘤术 vs 新辅助化疗/间歇性减瘤术)和术后残留病灶状态(无可见残留病灶 vs 肉眼可见残留病灶)评估无进展生存期。

主要发现

  • PRIMA 研究共 733 例患者,其中 236 例(32.2%)接受初次减瘤术,481 例(65.6%)入组前接受新辅助化疗/间歇性减瘤术。
  • 初次减瘤术亚组中尼拉帕利 vs 安慰剂中位无进展生存期为 13.7 vs 8.2 个月(HR 0.67,95%CI 0.47-0.96)。
  • 新辅助化疗/间歇性减瘤术亚组中尼拉帕利 vs 安慰剂中位无进展生存期为 14.2 vs 8.2 个月(HR 0.57,95%CI 0.44-0.73)。
  • 接受新辅助化疗/间歇性减瘤术且无可见残留病灶者(n=304)进展 HR 为 0.65(95%CI 0.46-0.91)。
  • 初次减瘤术后肉眼可见残留病灶者(n=183)进展 HR 为 0.58(95%CI 0.39-0.86),新辅助化疗/间歇性减瘤术后肉眼可见残留病灶者(n=149)进展 HR 为 0.41(95%CI 0.27-0.62)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the association between surgical timing and postoperative residual disease status on the efficacy of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer at high risk of recurrence. METHODS: Post hoc analysis of the phase 3 PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016) study of niraparib in patients with newly diagnosed primary advanced ovarian, primary peritoneal, or fallopian tube cancer with a complete/partial response to first-line platinum-based chemotherapy. Progression-free survival (PFS) was assessed by surgical status (primary debulking surgery [PDS] vs neoadjuvant chemotherapy/interval debulking surgery [NACT/IDS]) and postoperative residual disease status (no visible residual disease [NVRD] vs visible residual disease [VRD]) in the intent-to-treat population. RESULTS: In PRIMA (N = 733), 236 (32.2%) patients underwent PDS, and 481 (65.6%) received NACT/IDS before enrollment. Median PFS (niraparib vs placebo) and hazard ratios (95% CI) for progression were similar in PDS (13.7 vs 8.2 months; HR, 0.67 [0.47-0.96]) and NACT/IDS (14.2 vs 8.2 months; HR, 0.57 [0.44-0.73]) subgroups. In patients who received NACT/IDS and had NVRD (n = 304), the hazard ratio (95% CI) for progression was 0.65 (0.46-0.91). In patients with VRD following PDS (n = 183) or NACT/IDS (n = 149), the hazard ratios (95% CI) for progression were 0.58 (0.39-0.86) and 0.41 (0.27-0.62), respectively. PFS was not evaluable for patients with PDS and NVRD because of sample size (n = 37). CONCLUSIONS: In this post hoc analysis, niraparib efficacy was similar across PDS and NACT/IDS subgroups. Patients who had NACT/IDS and VRD had the highest reduction in the risk of progression with niraparib maintenance.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. O'Cearbhaill RE, Pérez-Fidalgo JA, Monk BJ, et al. Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study. Gynecol Oncol. 2022. PMID: 35550709. doi:10.1016/j.ygyno.2022.04.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。